IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0136207.html
   My bibliography  Save this article

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs

Author

Listed:
  • Sarah Gooding
  • I-Jun Lau
  • Mimi Sheikh
  • Pamela Roberts
  • Julia Wong
  • Emmy Dickens
  • Ash Bullement
  • Jamie Elvidge
  • Dawn Lee
  • Karthik Ramasamy

Abstract

Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was £23,472 [range: £1,411–£90,262], split between drug costs £11,191 and other resource use costs £12,281. The cost per assumed quality-adjusted life year (QALY) during DRMM was £66,983. These data provide a standard of care comparison when evaluating the cost-effectiveness of new drugs in DRMM.

Suggested Citation

  • Sarah Gooding & I-Jun Lau & Mimi Sheikh & Pamela Roberts & Julia Wong & Emmy Dickens & Ash Bullement & Jamie Elvidge & Dawn Lee & Karthik Ramasamy, 2015. "Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs," PLOS ONE, Public Library of Science, vol. 10(9), pages 1-9, September.
    • Handle: RePEc:plo:pone00:0136207
    DOI: 10.1371/journal.pone.0136207
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136207
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0136207&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0136207?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Ruth Brown & Sean Stern & Sujith Dhanasiri & Steve Schey, 2013. "Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 507-514, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. M. Campioni & I. Agirrezabal & R. Hajek & J. Minarik & L. Pour & I. Spicka & S. Gonzalez-McQuire & P. Jandova & V. Maisnar, 2020. "Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(2), pages 219-233, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0136207. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.